Netarsudil mesylate

Drug Profile

Netarsudil mesylate

Alternative Names: AR-13224; AR13324; Netarsudil ophthalmic solution - Aerie Pharmaceuticals; Rhopressa

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Rho-associated kinase inhibitors; Transforming growth factor beta type II receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Glaucoma; Ocular hypertension
  • Preclinical Neurological disorders

Most Recent Events

  • 16 May 2017 The US FDA assigns PDUFA action date of 28 February 2018 for Netarsudil mesylate ophthalmic solution for Glaucoma and Ocular hypertension
  • 15 May 2017 US FDA completes 60–day review of netarsudil mesylate NDA
  • 02 May 2017 Aerie Pharmaceuticals plans phase I and II trials for netarsudil mesylate in Japan by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top